LEADING END-TO-END CDMO FOR PROTEIN-BASED BIOLOGICS AND ATMPs
Science-driven. Flexible. Built around your program.
Offerings
Our services
Cell Line & Strain Development
Developing high-producing mammalian cell lines and optimized microbial expression systems.
Process Development (USP & DSP)
Developing and optimizing robust bioprocesses for scalable manufacturing.
Analytical Development
Development, qualification and validation of phase-appropriate analytical methods.
cGMP MANUFACTURING
cGMP drug substance / product manufacturing for clinical and commercial supply with scalable production capabilities.
Viral Clearance Studies
Early and late-phase VCS for validation of purification processes to ensure robust downstream performance.
Quality & Regulatory CMC Support
Integrated QA, QC, and CMC regulatory excellence from development through commercialization.
220+
Successful projects globally.
22
Years of CDMO experience
110+
Satisfied clients worldwide
200+
Bioprocessing experts
4
EMA & FDA compliant sites
Don't take our word for it
Hear it from our clients.
“
Northway has treated our program as their own, responding to our specific needs with productive technical insight.
“
Chief Executive Officer
North American Biotech Company
“
What sets Northway apart is their ability to combine scientific rigor with real flexibility. They adapted to our evolving requirements without compromising on quality
“
VP of Development
German Biopharmaceuticals Company
Innovative and Fast-Growing CDMO
We operate four state-of-the-art facilities designed to support your program at every stage. Our European and US-based sites work seamlessly together, delivering integrated solutions from cell line development to cGMP manufacturing at scale. Wherever you are, we are within reach.
End-to-end mammalian and microbial biologics development and cGMP manufacturing, from cell line and process development to drug substance and aseptic drug product.
End-to-end mammalian and microbial biologics development and cGMP manufacturing, integrating drug substance and drug product capabilities.
End-to-end plasmid DNA and viral vector development and cGMP manufacturing, with dedicated BSL-2 viral clearance and BSL-3 laboratory capabilities.
End-to-end development and cGMP manufacturing of autologous and allogeneic cell therapies, with integrated 3D bioprinting capabilities.
The most advanced cell therapy infrastructure in the Baltic region is being developed in Vilnius. Northway Biotech, a leading protein-based biologics and ATMPs CDMO, is finalizing the installation of a…
June 6, 2026
Vilnius continues to cement its reputation as one of Europe’s fastest-rising life sciences hubs. International publication Real FDI has named two major developments in the Lithuanian capital – Bio City…
May 12, 2026
One of Lithuania's largest construction companies, Naresta, has completed the construction of a logistics centre for the Stem Cell Research Center, a company belonging to the Northway group of companies…
February 14, 2026
The joining of Northway Biotech to a Lithuanian science and business consortium collaborating with the Massachusetts Institute of Technology (MIT, USA) marks a new stage in international life sciences cooperation.…
January 29, 2026
Hørsholm, Denmark, 28 January 2026 – ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and…
January 28, 2026
Vilnius, Lithuania, October 14, 2025 – Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO), is delighted to announce its recognition as a winner of the Outsourced Pharma and…
October 25, 2025
Contact us
Please tell us about your project and the challenges you are facing. The more detail you share, the better we can tailor our response. A member of our team will follow up shortly to discuss how Northway Biotech can support your biopharmaceutical product’s success.